Who are ALC-2203-AC's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BENZHYDROCODONE, NALBUPHINE HYDROCHLORIDE, Opioid group, Nalmefene HCl injection, Standard Opioid, opioid pain pills.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/alc-2203-ac.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

ALC-2203-AC — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ALC-2203-AC (ALC-2203-AC) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kappa opioid receptor agonist. Area: Pain.

phase 2 Kappa opioid receptor agonist Kappa opioid receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

ALC-2203-AC (ALC-2203-AC) — Korea Arlico Pharm. Co., Ltd. ALC-2203-AC is a selective and potent agonist of the kappa opioid receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ALC-2203-AC TARGET	ALC-2203-AC	Korea Arlico Pharm. Co., Ltd	phase 2	Kappa opioid receptor agonist	Kappa opioid receptor
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
NALBUPHINE HYDROCHLORIDE	NALBUPHINE HYDROCHLORIDE		marketed		kappa opioid receptors, mu opioid receptors	1979-01-01
Opioid group	Opioid group	Beijing Friendship Hospital	marketed	Opioid agonist	Mu opioid receptor (primary), delta opioid receptor, kappa opioid receptor
Nalmefene HCl injection	Nalmefene HCl injection	Leiden University Medical Center	marketed	Opioid receptor antagonist	Mu, delta, and kappa opioid receptors
Standard Opioid	Standard Opioid	Prisma Health-Upstate	marketed	Opioid analgesic	Mu opioid receptor (primary); delta and kappa opioid receptors (secondary)
opioid pain pills	opioid pain pills	Rush University Medical Center	marketed	Opioid analgesic	Mu opioid receptor (primary); delta and kappa opioid receptors (secondary)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kappa opioid receptor agonist class)

Acologix, Inc. · 2 drugs in this class
Korea Arlico Pharm. Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ALC-2203-AC — Competitive Intelligence Brief. https://druglandscape.com/ci/alc-2203-ac. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing